Potential limitation of CCR5 antagonists: Drug resistance more often linked to CXCR4-utilizing than to CCR5-utilizine HIV-1

AIDS

Volumn 22, Issue 17, 2008, Pages 2393-2395

  Wagner, Thor A ^a,b   Frenkel, Lisa M ^a,b,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^c Departments of Pediatrics and Laboratory Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; MARAVIROC; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG EFFICACY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS GENOME; VIRUS MUTATION;

DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; RECEPTORS, CCR5; RECEPTORS, CXCR4;

EID: 56549122073     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328312c72c     Document Type: Article

References (9)

1. Lalezari J, Goodrich J, DeJesus E, Lampiris H, Gulick R, Saag M, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic art-experienced patients infected with CCR%-tropic HIV-1: 24-week results of a phase 2b/3 study in US and Canada. In: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, California, USA; 2007.
2. Nelson M, Fatkenheuer G, Konourina I, Lazzarin A, Clumeck N, Horban A, et al. Efficacy and Safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-week results. In: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, California, USA; 2007.
3. Westby M, Lewis M, Whitcomb J, Youle Mike, Pozniak AL, James IT, et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006; 80:4909-4920.
4. Frenkel LM, Wang Y, Learn GH, McKernan JL, Ellis GM, Mohan KM, et al. Multiple viral genetic analyses detecting low-level HIV-1 replication during effective HAART. J Virol 2003; 77:5721-5730.
5. Tobin NH, Learn GH, Holte SE, Wang Y, Melvin AJ, McKernan JL, et al. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J Virol 2005; 79:9625-9634.
6. Wagner T, Tobin N, McKernan J, Mohan, K, Learn, G, Mullin, J, et al. HIV-1 derived from lung during effective ART has distinctive characteristics. In: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, California, USA; 2007.
7. Bull M, Learn G, McElhone S, Hitti, J, Lockhart, D, Holte, S, et al. Distribution and analysis of the hiv-1 variants in the uterine cervix and as related to HIV-1 in the peripheral blood. In: 15th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts, USA; 2008.
8. Johnson VA, Brun-Vezinet F, Clotet B, Günthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 2007; 15:119-125.
9. Jensen MA, van 't Wout AB. Predicting HIV-1 coreceptor usage with sequence analysis. AIDS Rev 2003; 5:104-112.